These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22916844)

  • 21. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
    Roberts JD; Wells GA; Le May MR; Labinaz M; Glover C; Froeschl M; Dick A; Marquis JF; O'Brien E; Goncalves S; Druce I; Stewart A; Gollob MH; So DY
    Lancet; 2012 May; 379(9827):1705-11. PubMed ID: 22464343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost is not a barrier to implementing clopidogrel pharmacogenetics.
    Cavallari LH; Schumock GT
    Pharmacotherapy; 2012 Apr; 32(4):299-303. PubMed ID: 22461119
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
    Nishiya Y; Hagihara K; Kurihara A; Okudaira N; Farid NA; Okazaki O; Ikeda T
    Xenobiotica; 2009 Nov; 39(11):836-43. PubMed ID: 19845434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAPID GENE trial marks the validation of the first point-of-care genetic test in clinical medicine.
    Harrison N
    Pharmacogenomics; 2012 Jan; 13(1):11-2. PubMed ID: 22176618
    [No Abstract]   [Full Text] [Related]  

  • 26. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
    Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD
    JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High on-treatment platelet reactivity (HPR): what does it mean, and does it matter?
    Goto S; Tomiya A
    Thromb Haemost; 2013 Feb; 109(2):177-8. PubMed ID: 23306954
    [No Abstract]   [Full Text] [Related]  

  • 28. P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients?
    Kristensen SD; Grove EL; Hvas AM
    Thromb Haemost; 2012 Aug; 108(2):203-5. PubMed ID: 22739804
    [No Abstract]   [Full Text] [Related]  

  • 29. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prasugrel, clopidogrel, and combining Swedish apples with American oranges.
    Serebruany VL
    Eur Heart J; 2006 Aug; 27(15):1886-7; author reply 1887-8. PubMed ID: 16801327
    [No Abstract]   [Full Text] [Related]  

  • 31. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
    Dridi NP; Johansson PI; Clemmensen P; Stissing T; Radu MD; Qayyum A; Pedersen F; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2014; 25(7):506-12. PubMed ID: 24245960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
    Schulz S; Richardt G; Laugwitz KL; Morath T; Neudecker J; Hoppmann P; Mehran R; Gershlick AH; Tölg R; Anette Fiedler K; Abdel-Wahab M; Kufner S; Schneider S; Schunkert H; Ibrahim T; Mehilli J; Kastrati A;
    Eur Heart J; 2014 Sep; 35(34):2285-94. PubMed ID: 24816809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prasugrel versus clopidogrel.
    Pasceri V; Patti G; Di Sciascio G
    N Engl J Med; 2008 Mar; 358(12):1298-9; author reply 1299-301. PubMed ID: 18357638
    [No Abstract]   [Full Text] [Related]  

  • 36. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.
    Guzauskas GF; Hughes DA; Bradley SM; Veenstra DL
    Clin Pharmacol Ther; 2012 May; 91(5):829-37. PubMed ID: 22453194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
    Montalescot G; Sideris G; Cohen R; Meuleman C; Bal dit Sollier C; Barthélémy O; Henry P; Lim P; Beygui F; Collet JP; Marshall D; Luo J; Petitjean H; Drouet L
    Thromb Haemost; 2010 Jan; 103(1):213-23. PubMed ID: 20062936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
    Bergmeijer TO; Janssen PW; Schipper JC; Qaderdan K; Ishak M; Ruitenbeek RS; Asselbergs FW; van 't Hof AW; Dewilde WJ; Spanó F; Herrman JP; Kelder JC; Postma MJ; de Boer A; Deneer VH; ten Berg JM
    Am Heart J; 2014 Jul; 168(1):16-22.e1. PubMed ID: 24952855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.